Navin Pinto, MD, joined Gates Institute in December 2023 as medical lead. In this role, he works in partnership with the CU Anschutz Investigational New Drug and Device Office to oversee Gates Institute-supported clinical trials. He is an authority on CAR T-cell therapy for patients with relapsed and refractory cancer, and recently joined the faculty from Seattle Children’s Hospital/University of Washington. He is a professor of Pediatrics at CU Anschutz School of Medicine and an attending physician at Children's Hospital Colorado, where he leads the Solid Tumor Section. He is a graduate of Saint Louis University School of Medicine and maintains board certification in Pediatrics, Pediatric Hematology/Oncology and Clinical Pharmacology.